# US 9,752,184 B2 · Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,752,184 B2 - Document ID: US9752184B2 - Status: Granted - Kind: B2 - Application number: 14/456,806 - Filed: 2014-08-11 - Published: 2015-01-29 - Granted: 2017-09-05 - Earliest claimed: 2001-03-02 - Assignees: Ibis Biosciences, Inc. - Applicants: Ibis Biosciences, Inc.; Nina M. Hofstadler - Inventors: David J. Ecker; Richard H. Griffey; Rangarajan Sampath; Steven A. Hofstadler; John McNeil; Stanley T. Crooke; Lawrence B. Blyn; Thomas A. Hall; Yun Jiang; James C. Hannis; Neill K. White; Vivek Samant; Mark W. Eshoo; Jared J. Drader - Web page: https://patentgrep.com/patent/US9752184B2 ## CPC - C12Q 1/686: Polymerase chain reaction [PCR] - C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) - C12Q 1/6844: Nucleic acid amplification reactions - C12Q 1/6858: Allele-specific amplification - C12Q 1/6872: involving mass spectrometry - C12Q 1/6888: for detection or identification of organisms - C12Q 1/689: for bacteria - C12Q 2600/156: Polymorphic or mutational markers - G01N 2333/28: from Vibrionaceae (F) - G01N 2333/32: from Bacillus (G) - G01N 2333/35: from Mycobacteriaceae (F) - G01N 2333/36: from Actinomyces; from Streptomyces (G) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases. ## Claims ### Claim 1 A system, comprising: a) a nucleic acid purification component for purifying a nucleic acid from an unknown bioagent; b) a nucleic acid amplification component for amplifying a target nucleic acid sequence region from an unknown bioagent to generate an amplicon comprising said target nucleic acid sequence region, and at least one pair of purified oligonucleotide primers that hybridizes to said at least one target sequence region of a plurality of known bioagents, said target nucleic acid sequence region comprising two conserved regions that are hybridizable with said primer pair and that flank a variable region that uniquely varies between a plurality of known bioagents; c) a base composition determination component for determining a base composition of said target nucleic acid sequence region comprising a computer processor configured to determine the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and/or mass tag residues thereof of said amplicon; d) a base composition identification component comprising a database of base compositions from a plurality of known bioagents wherein said base compositions identify the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and/or mass tag residues thereof, said database comprising a plurality of measured base compositions of amplification products of known bioagents calculated or obtained by amplification of at least one target nucleic acid sequence region of a known bioagent nucleic acid gene sequence using a primer pair that hybridizes to said at least one target nucleic acid sequence region of a plurality of known bioagents said target nucleic acid sequence region comprising two conserved regions that are hybridizable with said primer pair and that flank a variable region that uniquely varies between a plurality of known bioagents, wherein said computer processor compares said base compositions from said plurality of known bioagents to a base composition of an unknown bioagent to determine the identity of said unknown bioagent; and e) a computer program on a computer readable medium configured to direct said computer processor to coordinate the operation of said nucleic acid purification component, said nucleic acid amplification component, said base composition determination component, and said base composition identification component. ### Claim 2 (depends on 1) The system of claim 1, wherein said nucleic acid purification component comprises one or more buffer manipulations, one or more salt manipulations, one or more thermal manipulations, one or more pH manipulations, one or more mechanical manipulations, one or more centrifugation manipulations, or one or more magnetic manipulations. ### Claim 3 (depends on 1) The system of claim 1, wherein said nucleic acid amplification component comprises a thermocycler. ### Claim 4 (depends on 1) The system of claim 1, wherein the amplification step is quantitative. ### Claim 5 (depends on 1) The system of claim 1, wherein said nucleic acid amplification component comprises one or more salts, one or more buffers, one or more dNTPs, or one or more enzymes. ### Claim 6 (depends on 1) The system of claim 1, wherein said database of base compositions comprises at least 10 base compositions. ### Claim 7 (depends on 1) The system of claim 1, wherein said database of base compositions comprises at least 50 base compositions. ### Claim 8 (depends on 1) The system of claim 1, wherein said database of base compositions comprises at least 100 base compositions. ### Claim 9 (depends on 1) The system of claim 1, wherein said database of base compositions comprises at least 500 base compositions. ### Claim 10 (depends on 1) The system of claim 1, wherein said database of base compositions comprises at least 1000 base compositions. ### Claim 11 (depends on 1) The system of claim 1, wherein said plurality of known bioagents comprises bioagents that differ by genus, species, sub-species, strain, sub-type or nucleotide polymorphism. ### Claim 12 (depends on 1) The system of claim 1, wherein said plurality of known bioagents comprises one or more viral bioagents, one or more bacterial bioagents, one or more fungal bioagents, one or more protozoal bioagents, one or more parasitic bioagents, one or more mammalian bioagents, or one or more human bioagents. ### Claim 13 (depends on 1) The system of claim 1, wherein said database of base compositions comprises the number but not the nucleic acid sequence order of A residues, C residues, T residues, G residues, U residues, analogs thereof and/or mass tag residues thereof. ### Claim 14 (depends on 1) The system of claim 1, wherein said at least one pair of purified oligonucleotide primers hybridizes to at least one target sequence region within a gene.